A Phase I Study of Ixazomib and Erlotinib in Advanced Solid Tumor Patients
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Erlotinib (Primary) ; Ixazomib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 07 Mar 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2020.
- 07 Mar 2017 Status changed from not yet recruiting to recruiting.
- 24 Oct 2016 New trial record